Fresenius Tempers Expectations For Adalimumab Biosimilar

 
• By Aidan Fry

As a late entrant to the European adalimumab market, Fresenius is cooling expectations for sales of its Idacio biosimilar while it continues work on late-stage candidates pegfilgrastim and tocilizumab.

Hand
Investors should not expect a major contribution to turnover this year from Fresenius Kabi's Idacio adalimumab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products